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Neuropathology and behavioural features of transgenic murine models of Alzheimer’s disease
Our understanding of the underlying biology of Alzhei-
mer’s disease (AD) has been steadily progressing; how-
ever, this is yet to translate into a successful treatment
in humans. The use of transgenic mouse models has
helped to develop our understanding of AD, not only in
terms of disease pathology, but also with the associated
cognitive impairments typical of AD. Plaques and neu-
rofibrillary tangles are often among the last pathologi-
cal changes in AD mouse models, after neuronal loss
and gliosis. There is a general consensus that successful
treatments need to be applied before the onset of these
pathologies and associated cognitive symptoms. This
review discusses the different types of AD mouse models
in terms of the temporal progression of the disease,
how well they replicate the pathological changes seen
in human AD and their cognitive defects. We provide a
critical assessment of the behavioural tests used with
AD mice to assess cognitive changes and decline, and
discuss how successfully they correlate with cognitive
impairments in humans with AD. This information is
an important tool for AD researchers when deciding on
appropriate mouse models, and when selecting
measures to assess behavioural and cognitive change.
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Introduction
Dementia is a term used to describe a syndrome, caused
by various diseases of the brain, characterized by
significant decline in multiple cognitive areas including
memory, language, social cognition, executive and
perceptual functions. The most recent Diagnostic and
Statistical Manual of Mental Disorders, 5th ed. (DSM–V)
introduces the term ‘Major Neurocognitive Disorders’,
with some changes in criteria compared to DSM–IV [1],
including more specific details on the degree of impair-
ment observed in the aforementioned cognitive
domains, and the inability to explain such impairments
by any other means [2]. Population-based studies show
that Alzheimer’s disease (AD), dementia with Lewy bod-
ies and vascular dementia are the most common patho-
logical substrates for dementia [3–6]. AD is the most
common type of dementia and is associated with a
decline in cognitive abilities, such as memory and
visuo-spatial skills. Early-onset familial AD accounts for
<1% of AD diagnoses, and typically occurs before the
age of 65 years [7]. Late-onset AD most often occurs
over the age of 65 years and is much more common.
Murine models of AD recapitulate aspects of the dis-
ease, often through gene mutations associated with
familial AD, and can powerfully elucidate critical
aspects of pathogenesis. Although this type of AD is
less common, the pathological phenotypes are similar
to sporadic AD. Extracellular beta amyloid plaques,
intracellular hyperphosphorylated tau, synaptic and
Correspondence: Kamar Ameen-Ali, Department of Psychology,
University of Sheffield, Floor D, Cathedral Court, 1 Vicar Lane,
Sheffield S1 2LT, UK. Tel: +44 114 22 26540; E-mail: k.ameen-
ali@sheffield.ac.uk
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
553
Neuropathology and Applied Neurobiology (2017), 43, 553–570 doi: 10.1111/nan.12440
neuronal loss and neuroinflammation, are all associ-
ated with the disease [8]. The amyloid cascade hypoth-
esis [9,10] proposed that amyloid (Ab) plaque
deposition is key to the pathogenesis of AD, with tau
pathology, inflammation and subsequent cell damage
as contributing factors. Neuronal and neurotransmitter
changes follow Ab deposition, leading eventually to cell
death. Cognitive decline may be a result of neuronal
dysfunction from toxic soluble Ab [11], or inhibited
synapse remodelling linked to Ab oligomers [12]. Ther-
apeutic trials have targeted the clearance of Ab, with
some success in both murine models [13,14] and in
humans [15,16]. However, immunotherapy targeting
Ab has not yet translated into improved cognitive func-
tioning [17–19]. A greater understanding of the role of
Ab molecular forms, their temporal role in AD develop-
ment and their interaction with other pathogenic
factors is required.
Oxidative stress is a key factor in AD, whereby the
balance between oxidants and antioxidants is disrupted,
leading to an excess of oxidants [20,21]. Several mech-
anisms may contribute towards oxidative stress, includ-
ing dysfunction of mitochondria [22,23], accumulation
of Ab [22,24] and hyperphosphorylated tau [25,26]
and neuroinflammation [27,28]. Biomarkers of oxida-
tive stress in AD have been identified; however, a rela-
tively recent systematic review by Chang et al. [29]
concluded that although serum markers of lipid peroxi-
dation are elevated in AD, there is insufficient evidence
to justify the use of biomarkers as predictors of AD
severity or outcome.
Recent studies have investigated the interacting and
modifying factors of the defining pathological features
of AD; Jonsson et al. [30] reported that a coding muta-
tion (A673T) in the amyloid precursor protein (APP)
gene has a protective effect against AD and cognitive
decline. Genome-wide association studies have reported
AD genetic risk factors, with Chapuis et al. [31]
recently identifying a gene (FERMT2) that has a role in
regulating APP metabolism and Ab production.
Researchers are yet to fully explore the interacting and
modifying factors of AD pathogenesis using AD mouse
models in great detail.
The current review will discuss how well, and in what
aspects, murine models of AD recapitulate the physiolog-
ical, neuropathological and cognitive changes associated
with human AD. A complete critical analysis of all AD
models and their phenotypes is beyond the scope of this
review, so the particular focus will be on commonly used
amyloid-based transgenes (overexpressors of APP and/or
its processing enzymes), wild-type human tau or mutant
microtubule associated protein tau (MAPT) expressors,
and selected combined and triple transgenes.
Murine models of AD
AD pathology primarily consists of amyloid plaques
and neurofibrillary tangles (NFT). Other pathological
features of AD include neuronal and synaptic loss, dys-
trophic neurites, reactive astrocytes, activated microglia
and BBB dysfunction [32].
Mutations in three genes have been identified as
causing autosomal dominant AD [APP, presenilins
(PSEN1 and PSEN2)] through altering Ab production,
and share similar pathological features to sporadic AD
[33]. These gene mutations have therefore been the
focus of many AD mouse models. Transgenic animals
based on amyloid production typically express high
levels of Ab peptide usually through altering the pro-
cessing of APP [34]. Altered APP processing is usually
achieved through introduction of human APP (hAPP),
or a PSEN gene mutation, which affects c-secretase
enzyme activity, and subsequently alters the cleavage
of APP to Ab1-42 [35,36]. Cleavage of APP occurs by
both b-secretase enzyme [also known as b-site amyloid-
cleaving enzyme 1 (BACE1)] at the N-terminus of the
Ab peptide, and the c-secretase enzyme (Ab C-termi-
nus) activity [36], resulting in a 42 amino acid peptide.
This peptide makes up the extracellular fibrillar Ab
which forms the senile, compact plaques with dense
cores. The ratio between Ab40 and Ab42, rather than
just overall Ab expression, is thought to be a significant
factor in determining plaque load and toxicity [34]. a-
secretase activity is involved in cleavage of APP to Ab
fragments between residues 16 and 17 of the Ab pep-
tide, resulting in a truncated Ab17-40 or Ab17-42
fragment. PSEN genes also have several other functions
in addition to cleavage of c-secretase, and there is cur-
rent debate over whether they may be altered by gene
mutations leading to AD [37], rather than, or in addi-
tion to, changes to the Ab40/Ab42 ratio [38].
Single mutations in the PSEN1 or PSEN2 genes
cause APP processing by c-secretase activity to shift
towards the more toxic Ab 1-42 rather than Ab 1-40
[39], although these mice do not develop plaques
unless crossed with APP overexpressor lines [40].
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PSEN1 and PSEN2 gene mutations are functionally
similar, although PSEN1 is more severe [41].
Neurofibrillary tangles are also a significant hall-
mark of AD, and are composed of hyperphosphory-
lated forms of tau protein [35]. There are no known
MAPT gene mutations associated with sporadic AD,
but they do occur in fronto-temporal dementia
(FTLD-tau) and Parkinson’s disease, linked to chromo-
some 17 (FTDP-17; [42]). Tau protein binds micro-
tubules stabilizing them in the axons, but in some
disease states hyperphosphorylated tau dissociates
from the microtubules and forms prefibrillar oligo-
meric and fibrillary aggregates such as NFTs and
paired helical filaments ([43]). Ab oligomers have
been reported to contribute to tau oligomerization
[44]. Improved animal models are essential for fur-
ther understanding the relationship between amyloid
and tau pathology. Transgenic mice that recapitulate
the NFT therefore express either wild-type human tau
or mutant MAPT [35]. A number of double-trans-
genic mice models go one step further and attempt
to model the functional interaction between APP and
mutant MAPT expression, to more closely mimic the
overall pathology seen in AD, with triple transgenes
also including a PSEN1 gene mutation.
AD mouse models that exhibit one or more of the
main features of the disease also exhibit additional neu-
ropathological changes associated with the disease,
such as changes to cells within the neurovascular unit
[45]. For example astrocytes, which are typically
involved in cerebral homoeostasis, become activated in
AD [46] and co-localize with amyloid plaques [47].
Early astrocyte damage and dysfunction have been
linked to AD pathogenesis [48–50]. Microglia are
immune cells that also become activated and co-localize
with amyloid plaques [51,52]. Some AD mouse models
associated with altered Ab production are known to
develop cerebral amyloid angiopathy (CAA) whereby
amyloid deposition builds up on arterial walls. It is a
pathological feature of AD that can also be found in
the elderly without AD, and can be associated with
cerebral haemorrhage [53]. Mouse models that exhibit
CAA (such as TgAPP23 and TgCRND8) are useful for
assessing small vessel disease and cerebral haemor-
rhage in relation to AD, but interpreting causal links
between pathological and behavioural phenotypes can
be difficult, as symptoms may be due to cerebral abnor-
malities [11].
Testing cognition in animals
The hippocampal formation is one of the earliest brain
regions to be affected by AD, with impairments in
working memory and declarative memory among the
first symptoms to be reported by AD patients [54]. Tests
of visuo-spatial processing are useful measures of cogni-
tive impairment in the disease, however, by the point
in which patients undergo neuropsychological assess-
ment, neuropathology may have been present for years
without notable symptomatology [55].
Hippocampal-dependent tasks measure early cogni-
tive changes in mouse models of neurodegenerative dis-
eases and so will be the sole focus of the review, with a
comprehensive overview of these and other tasks being
reported elsewhere [56,57]. Tasks used in mouse mod-
els of AD include the Morris water maze [58,59], the
radial arm maze (RAM) [60], the T-maze/Y-maze [61]
and the spontaneous object recognition (SOR) task [62].
The Morris water maze is a test of hippocampal-
dependent spatial memory whereby rodents typically
have to locate a submerged platform using external
visual cues (Figure 1). Escape latency and/or search
path are used as measures of learning acquisition, in
which good spatial learning is reflected by a decrease
in escape latency and/or the search path used to locate
the platform. Hippocampal-dependent spatial working
memory has been measured using a number of para-
digms, particularly the RAM, which involves baiting
the arms of the maze with food that does not get
replenished. Efficient searching through reduced entries
to previously visited arms suggests that the animal
remembers where it has previously visited. Alternation
tasks using the T-maze or the Y-maze utilize the ani-
mal’s natural exploratory behaviour to measure the
animal’s tendency to enter the less recently visited arm
(s). These spatial alternation tasks require minimal
training in contrast to the RAM.
The SOR task relies on rodent’s innate preference for
novelty, as they demonstrate recognition for a familiar
object through preferential exploration of a novel
object. The SOR task is not typically hippocampal-
dependent, unless the time delay between the sample
and test phases is increased from minutes to hours
[63]. Rodent behavioural tasks are thought to rely on
the same neural mechanisms as in humans, so they
can provide a reliable measure of cognitive function in
animal models of neurodegeneration that closely
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reflects the cognitive decline seen in human neurologi-
cal disease.
How well do models of AD recapitulate
physiological, neuropathological and
behavioural changes associated with the
disease?
Specific mouse models, categorized as those that over-
express Ab, those with mutations affecting secretase
processing of APP and those with NFT pathology
(through introducing human wild-type tau or mutant
MAPT), will now be discussed, considering how well
they reflect human AD in terms of pathology and
cognitive changes.
Altering Ab through APP processing
Human APP mutations mainly occur at one or both of
the two cleavage sites that result in Ab production. For
example, c-secretase cleavage site mutations, such as
V717I and V717F, alter the ratio between Ab40 and
Ab42 production to favour the more toxic Ab42 [34],
but many express the K670N/M671L Swedish double
mutation at the b-secretase cleavage site which results
in increased BACE cleavage and production of Ab40
Morris water maze Radial arm maze (c) (b) (a) 
(d) (e) 
T-maze
Y-maze Spontaneous object recognition
Sample phase Test phase
Start arm
Delay
Sample phase Test phase
A B
C
Submerged 
platform
Figure 1. Test apparatus for a series of rodent cognitive tasks. (a) The Morris water maze. Animals are required to locate a submerged
(hidden) platform. Escape latency and/or search path are used as measures of spatial memory. Memory impairment is demonstrated
through no decrease in escape latency. (b) Radial arm maze. The animal begins in the centre of the maze, with each arm baited with
food. The animal can explore these arms and consume the food reward, but the food is not replenished. Spatial working memory is
assessed through the number of times unbaited arms are re-entered. Memory impairment is demonstrated when unbaited arms are
repeatedly visited. The dashed lines represent the line to be crossed for an arm entry to be counted. (c) T-maze alternation task. During a
sample phase, the animal begins in the start arm and is forced to enter either the right or left arm (in this example, the left), receiving a
food reward. For the test phase, the animal again begins in the start arm, but has the choice between previously entered arm and the
novel arm. The animal receives a food reward for entering the arm not previously visited during the sample phase. Memory impairment
is demonstrated if the animal fails to alternate between the arms from sample to test phase. The dashed line represents the door blocking
entry to the right arm during the sample phase. (d) Y-maze alternation task. The animal begins in the centre of the maze in this
continuous version of the alternation task. For a period of time (e.g. 10 min) the animal can freely explore the three arms of the maze
(labelled here as ‘A’, ‘B’ and ‘C’). Memory impairment is demonstrated if the animal fails to display a tendency to alternate between the
less visited arms. (e) Spontaneous object recognition. Animals can freely explore two copies of an object in an open field in a sample
phase. Following a delay (of minutes or hours), the animal is returned to the open field and exposed to a copy of the sample object and a
novel object in the test phase. Recognition of the familiar object is shown through greater exploration of the novel object over the
familiar object. Memory impairment is demonstrated through equal exploration of both objects at test.
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and Ab42. Others combine both the Swedish mutation
with a c-secretase cleavage site mutation [38].
PDAPP
The first transgenic mouse model to develop robust
amyloid plaque deposition was generated by Games
et al. [64], and contained hAPP with mutations associ-
ated with familial, early-onset AD (FAD V717F Indi-
ana) using C57Bl/6, DDA/2J and Swiss-Webster mouse
strains (Table 1). The PDAPP (platelet-derived growth
factor promoter amyloid precursor protein) mice exhibit
amyloid deposition from 6 to 9 months of age, with
further pathologies characteristic of AD such as dys-
trophic neurites (immunoreactive against phosphory-
lated tau; [65]), the co-localization of activated
astrocytes and microglia with plaques and a decrease
in synaptic density [64]. There is no development of
NFTs or neuronal loss up to at least 18 months of age
[66].
There is an age-related memory impairment in the
SOR task, with all PDAPP mice initially performing as
well as controls in discriminating between novel and
familiar objects at 3 months of age, but by 6 months
onwards, the homozygous PDAPP mice fail to success-
fully discriminate between objects. When tested in the
RAM, only homozygous PDAPP mice show significant
reference memory impairments through entering
incorrect unbaited arms more often than controls, but
PDAPP mice show working memory impairments
through revisiting previously baited arms more often
than controls [35]. Chen et al. [67] reported spatial
memory impairments in the Morris water maze with 3-
month-old PDAPP mice impaired at learning the first
platform location. Dodart et al. [68] reported sensori-
motor impairments in PDAPP mice from 3 months of
age, as they failed to habituate to an open field typi-
cally exhibited through a decrease in locomotor activity
levels over time.
The reported cognitive and behavioural impairments
all precede the onset of disease pathology in PDAPP
mice, which suggests there is early dysfunction to
mechanisms linked to these impairments, and may con-
tribute to the plaque and cellular pathology which is
typical of AD.
Tg2576
Tg2576 mice were developed by Hsiao et al. [69], over-
expressing the Swedish APP mutation (K670N/M671L)
on a C57Bl/6 9 SJL background [35]. These mice
show an increase in Ab levels at 6 months, and plaque
deposition between 9 and 12 months of age across the
cortex and hippocampus [70]. These mice recapitulate
Table 1. Timeline of onset of amyloid pathology and cognitive test impairments in transgenic mouse models of AD
Transgenic mouse model Mutation
Amyloid
deposition
(months) SOR (months)
Water maze
(months)
T-maze
(months)
Y-maze
(months)
PDAPP APP (Indiana V717F) 6–9 6 3
Tg2576 APP (Swedish K670N-M671L) 9–12 12–15 6 10 10
TgAPP23 APP (Swedish K670N-M671L) 6–12 3–4 3
TgCRND8 APP (Swedish K670N-M671L
and Indiana V717F)
3–5 3–5 3
J20 APP (Swedish K670N-M671L
and Indiana V717F)
5–7 4 6–9
APP + PSEN1 APP (Swedish K670N-M671L),
PSEN1 M146L
6–8 15–17 3
TAPP APP (Swedish K670N-M671L),
MAPT P301L
6 7–8
Tg2576n/VLW tau APP (Swedish K670N-M671L),
G272V, MAPT P301L, R406W
9 16
3xTgAD APP (Swedish K670N-M671L),
MAPT P301L, PSEN1 M146V
5 Intact at
11 months
6–9
AD, Alzheimer’s disease; SOR, spontaneous object recognition; APP, amyloid precursor protein; PDAPP, platelet-derived growth factor
promoter amyloid precursor protein; PSEN1, presenilin; MAPT, microtubule associated protein tau; TAPP, tau amyloid precursor protein.
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many of the neuropathological features of AD, includ-
ing astrogliosis [71], microgliosis [72] and dystrophic
neurites [71]. Similar to the PDAPP mice, there is no
observed neuronal loss; however, there is also no signif-
icant decrease in synaptic density [73,74]. Ab increases
may be linked to synaptic dysfunction, if not necessar-
ily synapse loss [73,75].
Tg2576 mice show repetitive exploration behaviours
from 10 months of age in the spontaneous Y-maze
alteration task [69], and from 10 months onwards in
the T-maze alternation task [75]. Tg2576 mice exhibit
soluble Ab before 6 months of age, but do not develop
progressive spatial acquisition and memory perfor-
mance impairments until 6 months onwards [76]. In
the SOR task, Tg2576 mice fail to discriminate between
novel and familiar objects after a 24 h delay compared
to controls at 12–15 months of age [77]. Tg2576 mice
exhibited greater exploration in an open field [75] and
an increased interest in exploring the central areas
[78]. Tg2576 mice have also been reported to show
increased aggression towards cage mates [79].
Cognitive impairments in the Tg2576 mice occur
much later than the PDAPP mice, which may be
related to the significant decrease in synaptic density
observed in the PDAPP mice. Similar to the PDAPP
mice, the cognitive and behavioural impairments in the
Tg2576 mice either precede or coincide with the Ab
pathology, again suggesting there is early dysfunction
occurring prior to plaque deposition and glial response.
TgAPP23
TgAPP23 AD mice were generated using the Swedish
double mutation (K670N/M671L) altering the b-secre-
tase cleavage site, and the London (V717I) mutation
altering the c-secretase cleavage site, on a C57Bl/
6 9 DBA/2 background [80]. These mice overexpress
hAPP across the hippocampus and cortex and are
notable for their cerebrovascular phenotype [81]. Amy-
loid deposition is present from 6 months of age and
substantial by 12 months, particularly in cerebral ves-
sels which progressively decreases cerebral blood flow
and alters vessel morphology [82,83]. TgAPP23 mice
also display reactive gliosis and astrocytosis, dystrophic
neurites, and synaptic loss [81], as well as a degree of
neuronal loss in older TgAPP23 mice [84].
TgAPP23 mice show spatial impairments in water
maze latencies and path lengths from 3 months of age
prior to substantial plaque deposition [85]. In the SOR
task, TgAPP23 mice fail to discriminate between novel
and familiar objects after a 24 h delay at 3–4 months
of age [86]. Both SOR and water maze task impair-
ments occur from around 3 months of age, therefore,
preceding amyloid deposition. This is similar to the
PDAPP and Tg2576 mice, though with slightly differ-
ent ages of onset.
TgAPP23 mice exhibit a cerebrovascular phenotype
making them a useful model for AD with CAA, but it is
unclear how much of the neuropathology and cogni-
tive profiles can be attributed to the hAPP mutation or
the cerebrovascular changes [11].
TgAPP23 mice exhibit a decrease in exploratory
behaviour in the open field, at 6–8 weeks, 3 and
6 months of age, while also showing significant impair-
ments relative to control animals on the rotarod at 3
and 6 months [85]. TgAPP23 mice have also been
reported to show increased aggression from 6 months
of age, after the onset of both amyloid plaques and
other discussed behavioural impairments [87].
TgCRND8
TgCRND8 mice were developed on a C57Bl/6 9 C3H
background and contained both the APP Swedish dou-
ble mutation (K670N-M671L) and the V717F Indiana
mutation [35]. These mice present with Ab deposition
at 3 months of age, with dense core plaques present by
5 months in the cortex and hippocampus [88,89],
spreading to the cerebellum and brainstem by 8–
9 months of age [11], which is associated with
increased inflammatory response [90]. In addition,
astrocytic gliosis and microglial activation in regions
around plaques have been reported [89].
Chishti et al. [89] reported that these mice have sig-
nificant acquisition impairments in hidden platform
testing at 11 weeks, with longer swim paths and search
latencies compared to controls. In addition, TgCRND8
mice show spatial reference memory impairments at 6–
8 months of age, but were able to overcome this impair-
ment when the hidden platform was visibly cued [91].
At 3–5 months of age, TgCRND8 mice fail to dis-
criminate between novel and familiar objects on the
SOR task with a 1 h delay [92], and in the Y-maze
task, TgCRND8 mice perform comparably to controls
up to around 11 months of age, demonstrating intact
short-term spatial memory capacity [93]. Overall, and
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similar to the previously discussed AD models, any sig-
nificant cognitive impairments reported in the
TgCRND8 mice coincide with amyloid deposition,
occurring at an early age of around 3 months. How-
ever, the Ab pathology does occur at a younger age
compared to the previous models, so the timeline from
when the cognitive impairments are observed, to when
amyloid deposition occurs, is much shorter, almost
occurring simultaneously.
J20
The J20 transgenic mouse features a high level of Ab1-
42 overexpression resulting from the introduction of
both the Swedish (K670N and M671L) and Indiana
(V7171F) hAPP mutations in a C57Bl/6 9 DBA2J back-
ground. Diffuse amyloid deposits appear from 5 to
7 months of age in the hippocampus and the neocortex,
with larger neuritic plaques appearing after 9 months of
age (Figure 2). J20 mice also exhibit a decrease in synap-
tophysin immunoreactivity indicating changes in synap-
tic function [11]. J20 mice are also a useful epilepsy
model, due to abnormal neural hyperexcitability [94],
and cerebrovascular function and neurovascular cou-
pling in relation to neurodegeneration [95,96].
On the SOR task, J20 mice successfully discriminate
between novel and familiar objects after a 1 h delay up
to 15–16 months of age [97], but are unable to recog-
nize familiar objects after a 4 h delay at 6–8 months of
age [98]. When the delay is extended to 24 h, J20
mice are impaired from as early as 4 months old [99].
Overall, these findings suggest that J20 AD mice are
able to successfully recognize a previously encountered
object following a delay of up to 1 h, but not after a
delay of over 4 h.
Palop et al. [100] reported that J20 mice aged 6–
9 months of age are impaired in water maze hidden
platform location as well as spatial location retention
in probe trials. An alternative measure of spatial mem-
ory that relies on the animal’s natural exploratory
behaviour is the object-location (OL) task (a spatial
variant of the SOR paradigm). AD mice with APP
mutations show impairments on the OL from around
5 months of age [101]. Unlike the previously discussed
AD models, the age of onset for spatial memory impair-
ments in the water maze is not as early. Spatial mem-
ory impairments in the OL task are observed at a
slightly younger age, so it can be concluded that, over-
all, impairments observed on both recognition and spa-
tial memory appear to coincide closely with the
deposition on amyloid in the hippocampus and cortex,
from around 4 months onwards.
Secretases
Specific mutations in the PSEN genes (PSEN1 and
PSEN2; [102,103] result in changes in c-secretase
activity leading to preferential processing of Ab1–42
GFAP and Aβ dual label Iba1 and Aβ dual label (A) (B)
Figure 2. Glial pathology associated with Ab plaques in the hippocampus of a 12-month-old hAPP-J20 mouse. Ab plaques (6E10, red)
are associated with (A) reactive astrocytes (GFAP, brown) and (B) microglia (Iba-1, brown). Scale bar represents 50 lm. Images are
contrast enhanced.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2017; 43: 553–570
Review of mouse models of Alzheimer’s disease 559
fragments. Most PSEN gene mouse models are derived
from PSEN1 mutations.
APP + PSEN1
Holcomb et al. [40] crossed the PSEN1 transgene
(M146L) with hAPP Tg2576 mice, and at 4–5 months
of age APP + PSEN1 mice had detectable insoluble Ab.
At 6–8 months of age, APP + PSEN1 mice show ele-
vated levels of Ab compared to single transgenic
Tg2576 littermates [40]. Spatial memory impairments
appear as early as 12–14 weeks of age, with APP +
PSEN1 mice showing a significant reduction in the
number of alternations on the Y-maze spatial task
[104]. Arendash et al. [105] further supported these
findings, reporting that APP + PSEN1 mice showed a
significant reduction in the number of alternations in
the Y-maze task at 5–7 months of age, but also showed
impairments in acquisition of spatial locations in the
water maze at 15–17 months of age.
15–17-month-old APP + PSEN1 mice exhibited senso-
rimotor deficits through a significant impairment on a
balance beam test, and increased activity in the open field
[105]. A more recent study by Wang et al. [106] mea-
sured sensorimotor gating in the APP + PSEN1 mice at
3, 7 and 22 months of age, using the prepulse inhibition
(PPI) of the startle response (attenuated startle response
from a preceding stimulus). PPI was found to be lower in
7- and 22-month-old APP + PSEN1 mice compared to
age-matched controls, with the 7-month-old APP +
PSEN1 mice also exhibiting memory impairments in the
water maze task and increased Ab plaque deposition com-
pared to 3-month-old APP + PSEN1mice.
Correlating the onset of Ab pathology and impair-
ments in spatial memory in the water maze suggest
that these phenotypes are linked, with onset occurring
around 6–7 months of age. However, spatial memory
performance in the Y-maze reveals impairments from
as early as 3 months of age, highlighting how task-
specific demands can vary in sensitivity.
BACE1 KO 3 APP
Luo et al. [107] developed the BACE1 knock out on a
hAPP Tg2576 background. BACE1/Tg2576+ pheno-
typically should be ‘normal’, in that they show no signifi-
cant disease-associated pathology. These mice do not
develop plaques or produce soluble Ab peptides [108]. In
the Y-maze alternation task, BACE1/ Tg2576+ mice
at 4–6 months of age performed as well as wild-type
controls and significantly better than Tg2576 mice who
exhibit brain amyloid Ab (but not plaque deposition) at
this age. These results suggest that BACE1 deficiency in
a hAPP transgenic mouse model results in improved per-
formance on the Y-maze alternation task, which may be
linked to reduced Ab levels.
Tau and triple transgenes
Most transgenic mouse models used to investigate tau
and the formation of NFTs involve either introducing a
gene for human wild-type tau, or mutant MAPT [35].
It is important to note that single transgenic mice with
FTD-associated tau (e.g. the JNPL3 line expressing the
P301L FTD-associated tau mutation) are better under-
stood as models of FTD, rather than AD [38]. A num-
ber of studies have also modelled tau propagation
through transgenic lines that overexpress P301L
restricted to regions such as the entorhinal cortex
where neurons are first affected by NFTs [109], or
through injecting tau preformed fibrils into specific
brain regions of PS19 transgenic mice overexpressing
human P301S mutant tau, for example [110].
TAPP
Lewis et al. [111] crossed the hAPP Tg2576 mouse line
with the JNPL3 mouse line expressing the most common
FTD-associated human tau mutation (P301L), forming
the TAPP (tau amyloid precursor protein) bigenic line.
The TAPP mice develop Ab plaque deposition compara-
ble to Tg2576 mice and as early as 6 months of age
[111], but the NFT pathology is more severe than JNPL3
mice, suggesting that the APP pathology may contribute
towards exacerbating tangle formation [111]. Cognitive
performance is not widely reported in this model, but
they do have various motor disturbances [111]. Yuzwa
et al. [112] recently reported TAPP mice were impaired
on the water maze task at 7–8 months of age, which is
at a slightly later age of onset to Ab deposition and in
contrast to previously discussed AD models.
Tg2576/VLW tau
Amyloid overexpressing Tg2576 mice were crossed with
VLW mice with mutant 4R MAPT [113] containing a
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triple mutation (G272V, P301L, R406W) on a C57Bl/
6 9 CBA background. These mice exhibit widespread
Ab accumulation initially at 9 months of age, with wide-
spread deposition, and neuronal loss in the entorhinal
cortex and CA1 region of the hippocampus from
16 months of age [113]. Spatial memory tested in the
Morris water maze reveals longer escape latencies com-
pared to wild-type controls initially at 9 months of age,
but predominantly from 16 months of age [113]. The
spatial memory impairments in the water maze are first
observed at a comparable age of onset relative to Ab
deposition, but this is still at a later age of onset com-
pared to previously discussed AD models.
3xTgAD
The 3xTgAD mouse line was developed by Oddo et al.
[114], who generated a triple transgenic model by coin-
jecting two transgenes containing APP (Swedish) and
MAPT P301L FTDP-17 mutations into embryonic cells
from PS1M146V knock-in mice. 3xTgAD mice exhibit
increased levels of Ab1-40 and Ab1-42, and NFTs. Amy-
loid plaques are present as early as 3 months of age, with
NFTs appearing much later at 12 months of age in the
hippocampus and cortex [114]. These mice also have
altered synaptic function which progresses with age
[114], and spatial memory impairments on the water
maze from 6 months of age [115]. Davis et al. [116]
reported intact recognition memory at 11 months of age,
despite the presence of intracellular Ab from 5 months. In
addition, 3xTgAD mice showed impairments on the T-
maze task (being unable to successfully distinguish
between novel and familiar arms), and the radial arm
water maze from between 6 and 9 months of age [117].
Overall, Ab deposition occurs early in 3xTgAD mice prior
to any significant cognitive impairments, which are
reported from around 6 months of age. This is in contrast
to the previously discussed AD models. NFTs also develop
later, at around 12 months of age. Though 3xTgAD mice
present with the two main features of AD, these findings
suggest poor correlation between behavioural impair-
ments and disease pathology, perhaps because Ab and
tau develop independently of one another.
Translation into therapeutic developments
There are currently only a select number of drugs
available to treat AD, focusing on alleviating
symptoms, with no new drugs being approved since
2003. No drug has yet been identified to significantly
alter the course of the disease, and translate success-
fully into clinical applications. This may be due to sig-
nificant differences between rodent models and humans
in terms of how they metabolise the drugs, how the
drugs act upon certain mechanisms, and fundamental
differences in neural circuitry between species [118].
Immunotherapy has been investigated preclinically
in AD mouse models as a potential therapeutic strategy
through preventing Ab aggregation. For example,
administration of the monoclonal antibody bap-
ineuzumab in PDAPP resulted in a reduction in both
soluble and insoluble levels of Ab [119]. Immunothera-
pies targeting amyloid plaques have progressed to clini-
cal trials, showing some promising reductions in rate of
cognitive decline [120], and levels of Ab and tau fol-
lowing neuropathological investigations [18], but no
trials have shown results that are both significantly
efficacious and nonharmful. For example, a recent
meta-analysis highlighted the lack of clinical efficacy of
bapineuzumab [121] which failed Phase III trials,
alongside similar monoclonal antibody solanezumab
[122].
BACE1 is another therapeutic target, with adminis-
tration of TAK-070 (a nonpeptidic BACE1 inhibitor) to
Tg2576 mice resulting in a reduction in both soluble
and insoluble Ab, and a reduction in cognitive impair-
ments [123]. However, promising BACE1 inhibitor
verubecestat has recently failed in clinical trial,
although a trial with patients at an earlier stage of the
disease continues [124]. Hung and Fu [125] have
recently published a comprehensive review of AD drugs
in clinical trials up to June 2017, including the thera-
peutic targets, trial status and clinical outcomes.
Stem cells have been investigated as a potential ther-
apeutic strategy for AD. Administration of haplotype-
matched murine neuronal stem cells to aged 3xTgAD
mice reduced cognitive impairments, but had no signifi-
cant effect on Ab or tau pathology [126].
There have also been recent advances in the use of
optogenetics, a technique which modulates neuronal
activity, as a therapeutic approach for neurodegenera-
tive diseases, including AD [127]. However, this
research is currently in the very early stages of
research.
In summary, a number of therapeutic strategies have
been developed in AD mouse models and have shown
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promising results in terms of reducing Ab or tau, for
example, showing that these models are good for reca-
pitulating disease pathology. However, none of these
strategies have yet successfully translated to clinical
outcomes in AD patients, so there is a need for more
advanced animal models that better model disease com-
plexity.
Discussion
No one model provides an ideal and complete charac-
terization of AD as observed in humans, however, dif-
ferent models are useful for answering questions about
specific aspects of the disease.
Within each type of AD model there are variations
in terms of the onset of pathological features and cog-
nitive decline, of which some can be accounted for by
background strains as well as differing baseline abilities
in terms of learning, memory and locomotion [39].
Even with AD models of the same genetic background,
many cognitive tests are sensitive to small variations in
task protocol, which can yield contrasting results
[128]. Rodents are nocturnal and do not primarily rely
on vision, but olfaction, which raises issues around
their abilities to perform in tasks such as the Morris
water maze [129]. Mice, in particular, are known to
perform poorly in the water maze compared to rats,
due to tendencies to swim nearer to the wall (a classic
hallmark of anxiety; [130] and to be more buoyant
[131]. The age of the animals is also a determining fac-
tor in water maze performance [132], which may be
related to an age-related decline in motor abilities.
No AD mouse model exhibits the full range of patho-
logical phenotypes, making it difficult to correlate cog-
nitive decline and pathological changes. Only a small
number of AD models exhibit neuronal loss [39], with
it being rarely reported in APP models, such as PDAPP
and Tg2576 [67, 72], but more often reported in APP
models combined with PSEN1 gene mutations [133].
Ab impairs synaptic function, which is likely to be a
major contributor to the cognitive impairments
reported [36]. Studies have described a loss in synapto-
physin-immunoreactivity around compact plaques in
both PDAPP and Tg2576 mice, indicating changes to
synapse function relating to Ab [72]. Soluble Ab may
contribute towards cognitive impairments, which
would account for why they are observed prior to com-
pact plaque deposits [77]. Pathological and behavioural
features need consideration when selecting an AD
model to test a specific hypothesis, and will depend on
the precise mechanisms being investigated.
It is not clear how accurately the time course of
amyloid plaque deposition and cognitive decline reflects
human AD. Behavioural impairments are often
reported prior to plaque deposition across AD mouse
models, but it is likely that Ab pathology is present
prior to the onset of cognitive impairments in humans
[134]. It may, however, be likely that subtle changes
in cognition occur prior to patients reporting the first
notable changes with their physician.
Transgenic mice expressing both amyloid and tau
pathology (e.g. TAPP and 3xTgAD) may seem like the
ideal models to study human AD as they more closely
reflect the disease. Although these mice present with
the two main features of AD, these pathologies are
reported as developing independently [38], and so do
not fully mimic the disease progression seen in
humans.
A number of emerging hypotheses linking other
health conditions to dementia and AD present an
opportunity for AD models to be utilized as models for
other diseases. For example, recent studies suggest that
Ab may play a role in promoting cerebrovascular
atherosclerosis [135], which would make an APP
mouse model suitable for studying this relationship and
a number of other cerebrovascular and neurodegenera-
tive diseases, particularly as such conditions rarely pre-
sent independently in humans.
Two genetic variations which are important risk fac-
tors for sporadic AD are the allelic variations of
apolipoprotein (APOE), and the R47H allele of the trig-
gering receptor expressed on myeloid cells 2 (TREM2;
[136]). APOE colocalizes with Ab and microglia. Mice
that are haploinsufficient for human APOE show a sig-
nificant decrease in plaque deposition in APP/PSEN1
(L166P) and J20 mice [137,138], and APOE-knockout
mice have been reported to clear Ab faster than control
mice [139]. Disrupting the interaction between APOE
and Ab may be a viable potential therapeutic approach
to reduce Ab deposition.
There are conflicting reports regarding the effect of
TREM2 on overall Ab plaque deposition which has
been characterized in the APP/PSEN1 and 5xFAD
mouse models [140,141]. Ulrich et al. [142] reported
that TREM2 haploinsufficient APP/PSEN1 mice of 3
and 7 months of age showed no significant Ab
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deposition in the cortex. Further research supports
these findings with Jay et al. [143] reporting that 4-
month-old TREM2/ APP/PSEN1 mice showed no sig-
nificant cortical Ab deposition, and a decrease in hip-
pocampal Ab deposition compared to TREM2+/+ APP/
PSEN1 mice (26). In comparison, Wang et al. [144]
reported that 8-month-old TREM2/ 5xFAD mice
exhibited an increase in hippocampal Ab deposition,
with no significant effect on cortical Ab. Further work
is needed to elucidate the roles of APOE and TREM2
gene variations in AD, and refining animal models will
be key to progressing how the function of these genes
relate to certain pathological features of AD.
Touchscreen technology [145] could present as a
way of standardizing and improving rodent cognitive
and behavioural tests. A range of computer-automated
cognitive tasks have been developed for rodents which
are designed to mimic the neuropsychological tasks
used with humans, improving their translational capa-
bility. Such tasks are carried out in the same apparatus
with the same type of stimuli, improving the ability to
compare performance across tasks. Romberg et al.
[146] reported that TgCRND8 mice showed no impair-
ment on a visual discrimination test, but were impaired
on a test of object recognition, even with a short delay
of 1 min. It is possible that the touchscreen version of
the object recognition task is more difficult than the
standard version, potentially due to rodents naturally
being more dependent on olfaction than visual acuity,
but the technology remains promising.
There have been varying results regarding the effect
of sexual differences on AD mouse model phenotypes,
but it is necessary to understand how such differences
may contribute to making one sex more vulnerable or
protected from disease. Research suggests that female
AD mice have an increased vulnerability to AD pheno-
types, but Dubal et al. [147] propose this may be more
closely related to a greater beneficial effect of male hor-
mones, and a more deleterious effect of female hor-
mones in the brain of AD mouse models.
Developments in genome editing technology known
as CRISPR/Cas9 allows for mice to be genetically engi-
neered much more efficiently [148], as multiple gene
variations can be introduced simultaneously. This tech-
nology is particularly significant for developing mouse
models of late-onset AD, which is likely to involve
multiple gene variations. Improved predictive models
should lead to better translation between preclinical
and clinical studies, particularly for the more common
late-onset AD.
Conclusion
Mouse models of AD continue to be a central compo-
nent in furthering our understanding of the disease
and identifying new therapeutic targets for existing and
novel compounds. It is important, however, to treat AD
models as a reductionist tool for understanding the
pathogenesis of AD, and research should be guided by
human studies to look for the causal relationships
human work cannot often provide.
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